Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meeting

Nicox SA announced a poster presentation highlighting responder analyses results from the Dolomites phase 2 clinical trial on NCX 470 in patients with open-angle glaucoma or ocular hypertension at the American Academy of Ophthalmology 2021 Annual Meeting being held from November 12-15, 2021 in New Orleans.

The presentation will be available on demand from November 12, 2021 on the AAO website via a link dedicated to e-posters.

Poster title: NCX-470 for IOP-lowering: Results of Responder Analyses from the Phase 2 Dolomites Trial (Number PO 217) – Primary author: Dr. Thomas R. Walters, MD

Nicox’s lead clinical development product candidate, NCX 470, is a novel nitric oxide-donating prostaglandin analog in late-stage clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.